Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (PCSA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pcsa · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$225
Consensus
$225
+9083.7% upside
Low
$225
Median: $225 · Last Close: $2.45
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.42 | ↓ 1.14% |
1-day model range: $2.35–$2.49. Peak: $2.49 (-1.14%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · PCSA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-06 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-11-17 | Maxim Group | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Processa Pharmaceuticals, Inc. (PCSA) stock. Of the recent 17 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover PCSA.
Analyst Recommendation Trends
PCSA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$15M
↑ 44.0% YoY
Revenue Next Year
$10M
↓ 32.9% YoY
EPS This Year
$-10.25
EPS Next Year
$-6.00
↓ 41.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast PCSA EPS of $-10.25 for the current fiscal year, based on estimates from 1 analysts. The PCSA revenue forecast is $15M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PCSA stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PCSA price target is $225.00 (+9083.7% upside), with an analyst consensus of Buy.
The PCSA short-term stock prediction for tomorrow is $2.42 (-1.14%).
Processa Pharmaceuticals, Inc. trades on NASDAQ under the ticker PCSA. The PCSA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
PCSA forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month PCSA price target is $225.00, with a high forecast of $225.00 and a low of $225.00. The median price target is shown in the chart above when available. This implies +9083.7% potential upside from the current price of $2.45.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.